Compugen Ltd. (CGEN) Stock Score, Valuation & Financial Research
Compugen Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 75/100.
Quick answer for CGEN
Compugen Ltd. currently has a Wall Street Score of 75/100. The stored market price is $2.41. Its financial score is 91/100. Its valuation score is 100/100. The latest WSS change is +0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Compugen Ltd. does
Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The company’s core activities center around its immuno-oncology pipeline, which includes several investigational treatments: COM701, an anti-PVRIG antibody currently undergoing Phase I clinical studies for solid tumors. COM902, a therapeutic antibody designed to target TIGIT, which is also in Phase I clinical trials as a monotherapy for advanced malignancies. Bapotulimab, an antibody targeting ILDR2, presently in Phase I clinical development for solid tumor indications. AZD2936, an innovative bispecific antibody targeting both TIGIT and PD-1, advancing through Phase I/II clinical studies for patients with
CGEN financial snapshot
- Wall Street Score:
- 75/100
- Current price:
- $2.41
- Market capitalization:
- $227.9M
- Revenue:
- $74.0M
- Net income:
- $35.2M
- Free cash flow:
- $31.3M
- Cash:
- $10.3M
- Total debt:
- $3.0M
- EPS:
- 0.38
- P/E ratio:
- 6.4x
- Financial score:
- 91/100
- Valuation score:
- 100/100
- Revenue score:
- 59/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $31.3M, showing positive cash generation.
- The balance sheet shows $10.3M of cash versus $3.0M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.1 points: CGEN increased 0.1 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 100/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 91/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-14.
How to research CGEN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.